GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vytrus Biotech SA (XMAD:VYT) » Definitions » Intrinsic Value: Projected FCF

Vytrus Biotech (XMAD:VYT) Intrinsic Value: Projected FCF : €0.00 (As of Jun. 17, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Vytrus Biotech Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-17), Vytrus Biotech's Intrinsic Value: Projected FCF is €0.00. The stock price of Vytrus Biotech is €4.00. Therefore, Vytrus Biotech's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Vytrus Biotech's Intrinsic Value: Projected FCF or its related term are showing as below:

XMAD:VYT's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.16
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Vytrus Biotech Intrinsic Value: Projected FCF Historical Data

The historical data trend for Vytrus Biotech's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vytrus Biotech Intrinsic Value: Projected FCF Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vytrus Biotech's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Vytrus Biotech's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vytrus Biotech's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Vytrus Biotech's Price-to-Projected-FCF falls into.


;
;

Vytrus Biotech Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Vytrus Biotech  (XMAD:VYT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Vytrus Biotech's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=4.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vytrus Biotech Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Vytrus Biotech's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vytrus Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
Sant Gaieta 121, 2nd, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.

Vytrus Biotech Headlines

No Headlines